Trial Profile
A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs REG-101 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Acronyms LEGACY
- Sponsors AstraZeneca; MedImmune
- 01 Dec 2021 Results assessing safety, pharmacokinetics, and pharmacodynamic effects of multiple doses of MEDI5884 in patients with stable coronary artery disease, published in the Arteriosclerosis Thrombosis and Vascular Biology
- 18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.